Welcome and Opening Keynote Address
10:30–11:15 a.m.
Channel 1

10:30–10:35 a.m. Welcome and Keynote Introduction
Ari M. Melnick, Weill Cornell Medical College, New York, NY

10:35–11 a.m. Rogue clones of self-reactive B cells with lymphoma driver mutations: A view of lymphoma precursors
Christopher Goodnow, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

11–11:15 a.m. Discussion / Q&A

Break
11:15–11:30 a.m.

Session 1: Teaching T-Cells New Tricks: Why Immunotherapy Fails in Lymphoma and How Do We Fix It?
Moderator: Helen E. Heslop, Baylor College of Medicine, Houston, TX
11:30 a.m.–1:05 p.m.
Channel 1

11:30–11:35 a.m. Moderator Introduction

11:35–11:50 a.m. The bad guys of follicular lymphoma microenvironment: Putative impact on therapy failure?
Karin Tarte, Université de Rennes, Rennes, France
11:50 a.m.–12:05 p.m. **Immune exhaustion and suppression in lymphoma**
Stephen M. Ansell, Mayo Clinic College of Medicine, Rochester, MN

12:05–12:20 p.m. **Optimizing immunostimulatory antibodies for cancer immunotherapy**
Mark Cragg, University of Southampton, Southampton, United Kingdom

12:20–12:35 p.m. **The immune cell microenvironment of classical Hodgkin lymphoma by single-cell analysis**
Christian Steidl, BC Cancer, Vancouver, BC, Canada

12:35–1:05 p.m. Discussion / Q&A

**Break**
1:05–1:20 p.m.

**Session 2: WHO vs. How? Changing Paradigms in Lymphoma Classification**
*Moderator: Georg Lenz, University of Münster, Münster, Germany*
1:20–2:55 p.m.
Channel 1

1:20–1:25 p.m. **Moderator Introduction**

1:25–1:40 p.m. **Molecular classification of T-cell lymphomas**
Keisuke Kataoka, National Cancer Center, Japan, Tokyo, Japan

1:40–1:55 p.m. **The role of gene expression in the classification of aggressive B-cell lymphoma**
David W. Scott, BC Cancer, Vancouver, BC, Canada

1:55–2:10 p.m. **Molecular classification of diffuse large B-cell lymphoma**
Bjoern Chapuy, University of Göttingen, Göttingen, Germany

2:10–2:25 p.m. **Microenvironmental signatures reveal biological and clinical subtypes of diffuse large B-cell lymphoma**
Leandro C. Cerchietti, Weill Cornell Medical College, New York, NY

2:25–2:55 p.m. Discussion / Q&A

**Break**
2:55–3:10 p.m.

**Session 3: Towards a Better Understanding of Adolescent Young Adult Lymphoma**
*Moderator: Sonali M. Smith, University of Chicago, Chicago, IL*
3:10–4:20 p.m.
Channel 1

3:10–3:15 p.m. **Moderator Introduction**
3:15–3:30 p.m.  **AYA lymphomas: Bridging the divide**  
Kara Kelly, Roswell Park Comprehensive Cancer Center, Buffalo, NY

3:30–3:45 p.m.  **Genomics of common AYA lymphomas: Hodgkin lymphoma and primary mediastinal B-cell lymphoma**  
Lisa G. Giulino-Roth, Weill Cornell Medical College, New York, NY

3:45–4:00 p.m.  **Unique features of pediatric-type follicular lymphoma**  
Abner Louissaint, Massachusetts General Hospital, Boston, MA

4:00–4:20 p.m.  Discussion / Q&A

Session 4: How Aberrant Metabolism Fuels Lymphoma  
*Moderator: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*  
3:10–4:05 p.m.

Channel 2

3:10–3:15 p.m.  **Moderator Introduction**

3:15–3:30 p.m.  **Oncogenic Rag GTPase signaling links cellular nutrients with FL microenvironment**  
Alejo Efeyan, Spanish National Cancer Research Center, CNIO, Madrid, Spain

3:30–3:45 p.m.  **Metabolic control of lymphomagenesis**  
Andrew Michael Intlekofer, Memorial Sloan Kettering Cancer Center, New York, NY

3:45–4:05 p.m.  Discussion / Q&A

Tuesday, August 18

Session 5: New CARs and Fine-Tuning Patient Selection for Therapy  
*Moderator: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY*  
10–11:20 a.m.

Channel 1

10–10:05 a.m.  **Moderator Introduction**

10:05–10:20 a.m.  **CARs and armored CARs: Improving CAR T cell therapy for cancer**  
Renier J. Brentjens

10:20–10:35 a.m.  **CAR T-cells for T-cell lymphoma**  
Maksim Mamonkin, Baylor College of Medicine, Houston, TX
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:35–10:50 a.m. | **Determinants of CAR-T outcomes: Host, tumor, and product**  
|               | Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center,  
|               | Houston, TX                                                         |
| 10:50–11:20 a.m. | Discussion / Q&A                                                    |
| Break         | 11:20–11:50 a.m.                                                    |

**Session 6: Biology-Based Clinical Trials: A Myth or Hope for Reality?**  
Moderator: John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia  
11:50 a.m.–1:25 p.m.  
Channel 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50–11:55 a.m.</td>
<td>Moderator Introduction</td>
</tr>
</tbody>
</table>
| 11:55 a.m.–12:10 p.m. | **Can we hope for success in biologically stratified DLBCL studies?**  
|               | Andrew John Davies, University of Southampton School of Medicine,  
|               | Southampton, United Kingdom                                          |
| 12:10–12:25 p.m. | **Why good trials fail: Impact of biomarker requirement on the selection bias of study patients**  
|               | Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science,  
|               | Rochester, MN                                                       |
| 12:25–12:40 p.m. | **Biomarker informed studies in peripheral T-cell lymphoma**  
|               | Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY |
| 12:40–12:55 p.m. | **Precision treatment of lymphoma using genomics**  
|               | Louis M. Staudt, National Cancer Institute, Bethesda, MD            |
| 12:55–1:25 p.m. | Discussion / Q&A                                                    |
| Break         | 1:25–1:40 p.m.                                                      |

**Session 7: Hacking the Lymphoma Epigenome to Create Better Therapies**  
Moderator: Ari M. Melnick, Weill Cornell Medical College, New York, NY  
1:40–3:15 p.m.  
Channel 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:40–1:45 p.m.</td>
<td>Moderator Introduction</td>
</tr>
</tbody>
</table>
| 1:45–2:00 p.m. | **The role of EZH2 gain-of-function mutations in lymphoma**  
|               | Wendy Béguelin, Weill Cornell Medical College, New York, NY          |
2:00–2:15 p.m.  Cooperative epigenetic interactions in normal and transformed germinal center B cells
Laura Pasqualucci, New York Presbyterian Hospital Herbert Irving Comprehensive Cancer Center, New York, NY

2:15–2:30 p.m.  CREBBP: Not all mutations are created equal
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

2:30–2:45 p.m.  What do the results from the trials tell us?
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom

2:45–3:15 p.m.  Discussion / Q&A

Break
3:15–3:30 p.m.

Session 8: Cancer Health Disparities in Lymphoma: How Do We Improve Outcomes?
Moderator: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX
3:30–4:40 p.m.
Channel 1

3:30–3:35 p.m.  Moderator Introduction

3:35–3:50 p.m.  Risk disparities in lymphoid cancers: What we know and what we don’t
Wendy Cozen, USC Norris Comprehensive Cancer Center, Los Angeles, CA

3:50–4:05 p.m.  Disparities in late effects incidence among adolescent and young survivors of lymphoma
Theresa H. M. Keegan, University of California Davis, Sacramento, CA

4:05–4:20 p.m.  Genome-estimated African ancestry is associated with distinct tumor mutations and poorer survival in patients with diffuse large B-cell lymphoma
Christopher R. Flowers

4:20–4:40 p.m.  Discussion / Q&A

Session 9: Hitting Back at MYC/BCL2 Lymphomas
Moderator: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
3:30–4:40 p.m.
Channel 2

3:30–3:35 p.m.  Moderator Introduction

3:35–3:50 p.m.  Targeting MYC deregulation in cancer
Dinis Calado, The Francis Crick Institute, London, United Kingdom
3:50–4:05 p.m.  **Modeling and targeting double-hit lymphoma**  
Bruno Amati, European Institute of Oncology, Milan, Italy

4:05–4:20 p.m.  **Targeting BCL-2 with venetoclax**  
Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, MA

4:20–4:40 p.m.  Discussion / Q&A

---

**Wednesday, August 19**

**Session 10: Dissecting Lymphoma Cell by Cell: A Dynamic Tale**  
*Moderator: Kojo Elenitoba-Johnson, University of Pennsylvania School of Medicine, Philadelphia, PA*

10–11:35 a.m.  
Channel 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–10:05 a.m.</td>
<td>Moderator Introduction</td>
<td></td>
</tr>
<tr>
<td>10:05–10:20 a.m.</td>
<td>Single-cell delineation of clonal variation and cellular tumor microenvironmental interactions in follicular lymphoma</td>
<td>Hanlee P. Ji, Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>10:20–10:35 a.m.</td>
<td>Pathology from the atomic scale on up</td>
<td>Garry P. Nolan, Stanford Hospital, Stanford, CA</td>
</tr>
<tr>
<td>10:35–10:50 a.m.</td>
<td>Follicular lymphoma dynamics through single-cell analysis</td>
<td>Bertrand Nadel, Centre d'Immunologie de Marseille-Luminy, Marseille, France</td>
</tr>
<tr>
<td>10:50–11:05 a.m.</td>
<td>Characterizing the tumor ecosystem in follicular lymphoma by CyTOF</td>
<td>Andrew P. Weng, BC Cancer, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>11:05–11:35 a.m.</td>
<td>Discussion / Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**Break**  
11:35–11:50 a.m.

**Session 11: Can We Find and Destroy Lymphoma Precursor Cells?**  
*Moderator: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX*

11:50 a.m.–1:25 p.m.  
Channel 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50–11:55 a.m.</td>
<td>Moderator Introduction</td>
<td></td>
</tr>
<tr>
<td>11:55 a.m.–12:10 p.m.</td>
<td>Tracking precursor stages of follicular lymphoma development</td>
<td></td>
</tr>
</tbody>
</table>
12:10–12:25 p.m.  Defining lymphoma reservoirs: Clues from the genomics  
Jessica Okosun, Barts Cancer Institute, Queen Mary University of London,  
London, United Kingdom

12:25–12:40 p.m.  Investigating malignant transformation in Waldenstrom's Macroglobulinemia  
Zachary R. Hunter, Dana-Farber Cancer Institute, Boston, MA

12:40–12:55 p.m.  Defining precursors in low-grade lymphomas that seed second lymphomas  
David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA

12:55–1:25 p.m.  Discussion / Q&A

Break  
1:25–1:40 p.m.

Session 12: Using Liquid Biopsies for Real-Time Monitoring of Lymphoma Biology and Clinical Decision-Making  
Moderator: David W. Scott, BC Cancer, Vancouver, BC, Canada  
1:40–3:15 p.m.  
Channel 1

1:40–1:45 p.m.  Moderator Introduction

1:45–2:00 p.m.  Approaches for personalized medicine in lymphoma through liquid biopsies  
David M. Kurtz, Stanford University, Stanford, CA

2:00–2:15 p.m.  Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA  
Ryan D. Morin, Simon Fraser University, Burnaby, BC, Canada

2:15–2:30 p.m.  Qualification and quantification of lymphoma under therapy by ctDNA analysis  
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

2:30–2:45 p.m.  ctDNA in indolent lymphoid cancers treated with targeted therapies  
Constantine S. Tam, St. Vincent's Hospital Sydney, East Melbourne, Australia

2:45–3:15 p.m.  Discussion / Q&A

Break  
3:15–3:30 p.m.

Session 13: Preclinical Models: How to Best Predict Therapeutic Response  
Moderator: Teresa Palomero, Columbia University, New York, NY
3:30–4:55 p.m.
Channel 1

3:30–3:35 p.m. Moderator Introduction

3:35–3:50 p.m. Developing preclinical models for peripheral T-cell lymphomas
Teresa Palomero

3:50–4:05 p.m. Molecular and genetic profiling in canine lymphoma unravels targets for
the human counterpart
Luca Aresu, University of Turin, Turin, Italy

4:05–4:20 p.m. Patient-derived tumor xenograft of human lymphomas
Giorgio Inghirami, Weill Cornell Medicine, New York, NY

4:20–4:35 p.m. Lymphoma organoids to study cooperative signaling and therapeutic
resistance in human DLBCLs
Ankur Singh, Georgia Institute of Technology, Atlanta, GA

4:35–4:55 p.m. Discussion / Q&A

Session 14: Understanding and Targeting Aberrant Receptor Signaling in Lymphoma
Moderator: Louis M. Staudt, National Cancer Institute, Bethesda, MD
3:30–4:40 p.m.
Channel 2

3:30–3:35 p.m. Moderator Introduction

3:35–3:50 p.m. MALT1 targeting for B-cell lymphomas
Lorena Fontan, Weill Cornell Medical College, New York, NY

3:50–4:05 p.m. Tracking MYC-lymphoma evolution in vivo: Role of the B-cell receptor
Stefano Casola, The FIRC Institute of Molecular Oncology (IFOM), Milan,
Italy

4:05–4:20 p.m. B-cell receptor– and co-receptor–driven metabolism reprogramming
Benjamin Gewurz, Brigham & Women’s Hospital, Boston, MA

4:20–4:40 p.m. Discussion / Q&A

Break
4:55–5:10 p.m.

Keynote Address and Closing Remarks
5:10–6 p.m.
Channel 1
5:10 p.m.  Keynote Introduction
Ari M. Melnick, Weill Cornell Medical College, New York, NY

5:10–5:35 p.m.  Cellular and molecular control of germinal center B-cell selection
Gabriel Victora, The Rockefeller University, New York, NY

5:35–5:50 p.m.  Discussion / Q&A

5:50–6:00 p.m.  Closing Remarks